Abstract
Purpose
We conducted a review and meta-analysis to establish the international pooled prevalence of psychotropic drugs in children and adolescents, and comment on recent trends.
Methods
Medline, Embase, and PsycINFO were searched for studies with annual prevalence estimates of attention deficit hyperactivity disorder (ADHD) medications, antidepressants, antipsychotics, sedative/hypnotics and anxiolytics in outpatient children and adolescents. Data were extracted regarding the representativeness, sampling frame, and the quality of reporting.
Results
A total of 59 studies reporting prevalence data for 23 countries were collected. Most studies were conducted in Europe (42) and were at high or moderate risk of bias (35).
The global random-effect pooled prevalence was 15.3‰ (95% confidence interval [CI], 7.6–25.7‰) for ADHD medications, 6.4‰ (95%CI 4.3–8.7) for antidepressants, and 5.5‰ (95%CI 3.6–7.8) for antipsychotics. Heterogeneity was extremely high (I2 > 99%). Large increases were found in the prevalence of ADHD medications in most countries, particularly up until 2010. The antidepressants’ trend was U-shaped in most countries with the lowest prevalence in 2007–2009 and rise more recently. Large to weak increases in the prevalence of antipsychotics were seen until 2011, and contrasting data were found more recently. Data on anxiolytics and sedative/hypnotics were limited.
Conclusions
The study provides global estimates of paediatric psychotropic drug prevalence and its trends. Systematic monitoring is lacking in most countries, and very heterogeneous reporting is common across studies.
Similar content being viewed by others
References
Steinhausen HC (2015) Recent international trends in psychotropic medication prescriptions for children and adolescents. Eur Child Adolesc Psychiatry 24(6):635–640. https://doi.org/10.1007/s00787-014-0631-y
Clavenna A, Bonati M (2009) Drug prescriptions to outpatient children: a review of the literature. Eur J Clin Pharmacol 65(8):749–755. https://doi.org/10.1007/s00228-009-0679-7
Hálfdánarson Ó, Zoëga H, Aagaard L, Bernardo M, Brandt L, Fusté AC, Furu K, Garuoliené K, Hoffmann F, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, Litchfield M, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Pearson SA, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Skurtveit S, Verdoux H, Wang LJ, Yahni CZ, Bachmann CJ (2017) International trends in antipsychotic use: a study in 16 countries, 2005-2014. Eur Neuropsychopharmacol 27(10):1064–1076. https://doi.org/10.1016/j.euroneuro.2017.07.001
Rapoport JL (2013) Pediatric psychopharmacology: too much or too little? World Psychiatry 12(2):118–123. https://doi.org/10.1002/wps.20028
Taylor E (2013) Pediatric psychopharmacology: too much and too little. World Psychiatry 12(2):124–125. https://doi.org/10.1002/wps.20030
Sharma AN, Arango C, Coghill D, Gringras P, Nutt DJ, Pratt P, Young AH, Hollis C (2016) BAP position statement: off-label prescribing of psychotropic medication to children and adolescents. J Psychopharmacol 30(5):416–421. https://doi.org/10.1177/0269881116636107
Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, Moreno C, Vitiello B, Vorstman J, Zuddas A, European Child and Adolescent Clinical Psychopharmacology Network (2015) Unmet needs in paediatric psychopharmacology: present scenario and future perspectives. Eur Neuropsychopharmacol 25(10):1513–1531. https://doi.org/10.1016/j.euroneuro.2015.06.009
Bonati M, Clavenna A (2005) The epidemiology of psychotropic drug use in children and adolescents. Int Rev Psychiatry 17(3):181–188. https://doi.org/10.1080/09540260500093768
Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, Baker P, Smith E, Buchbinder R (2012) Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 65(9):934–939. https://doi.org/10.1016/j.jclinepi.2011.11.014
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188
Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T (2013) Meta-analysis of prevalence. J Epidemiol Community Health 67(11):974–978. https://doi.org/10.1136/jech-2013-203104
Abbas S, Ihle P, Adler JB, Engel S, Günster C, Linder R, Lehmkuhl G, Schübert I (2016) Psychopharmacological prescriptions in children and adolescents in Germany. Dtsch Arztebl Int 113(22–23):396–403. https://doi.org/10.3238/arztebl.2016.0396
Bachmann CJ, Wijlaars LP, Kalverdijk LJ, Burcu M, Glaeske G, Schuiling-Veninga CCM, Hoffmann F, Aagaard L, Zito JM (2017) Trends in ADHD medication use in children and adolescents in five western countries, 2005-2012. Eur Neuropsychopharmacol 27(5):484–493. https://doi.org/10.1016/j.euroneuro.2017.03.002
Beau-Lejdstrom R, Douglas I, Evans SJ, Smeeth L (2016) Latest trends in ADHD drug prescribing patterns in children in the UK: prevalence, incidence and persistence. BMJ Open 6(6):e010508. https://doi.org/10.1136/bmjopen-2015-010508
Boland F, Galvin R, Reulbach U, Motterlini N, Kelly D, Bennett K, Fahey T (2015) Psychostimulant prescribing trends in a paediatric population in Ireland: a national cohort study. BMC Pediatr 15:118. https://doi.org/10.1186/s12887-015-0435-3
Burcu M, Zito JM, Metcalfe L, Underwood H, Safer DJ (2016) Trends in stimulant medication use in commercially insured youths and adults, 2010-2014. JAMA Psychiatry 73(9):992–993. https://doi.org/10.1001/jamapsychiatry.2016.1182
Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS (2007) Trends in medication treatment for ADHD. J Atten Disord 10(4):335–342. https://doi.org/10.1177/1087054707299597
Furu K, Karlstad Ø, Zoega H, Martikainen JE, Bahmanyar S, Kieler H, Pottegård A (2017) Utilization of stimulants and atomoxetine for attention-deficit/hyperactivity disorder among 5.4 million children using population-based longitudinal data. Basic Clin Pharmacol Toxicol 120(4):373–379. https://doi.org/10.1111/bcpt.12724
Hartz I, Skurtveit S, Steffenak AK, Karlstad Ø, Handal M (2016) Psychotropic drug use among 0-17 year olds during 2004-2014: a nationwide prescription database study. BMC Psychiatry 16(12):12. https://doi.org/10.1186/s12888-016-0716-x
Hodgkins P, Sasané R, Meijer WM (2011) Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 33(2):188–203. https://doi.org/10.1016/j.clinthera.2011.03.001
Hoshen MB, Benis A, Keyes KM, Zoëga H (2016) Stimulant use for ADHD and relative age in class among children in Israel. Pharmacoepidemiol Drug Saf 25(6):652–660. https://doi.org/10.1002/pds.3962
Kovess V, Choppin S, Gao F, Pivette M, Husky M, Leray E (2015) Psychotropic medication use in French children and adolescents. J Child Adolesc Psychopharmacol 25(2):168–175. https://doi.org/10.1089/cap.2014.0058
Librero J, Izquierdo-María R, García-Gil M, Peiró S (2015) Children’s relative age in class and medication for attention-deficit/hyperactivity disorder. A population-based study in a health department in Spain. Med Clin (Barc) 145(11):471–476. https://doi.org/10.1016/j.medcli.2015.02.022
Lillemoen PK, Kjosavik SR, Hunskår S, Ruths S (2012) Prescriptions for ADHD medication, 2004-08. Tidsskr Nor Laegeforen 132(16):1856–1860. https://doi.org/10.4045/tidsskr.11.1270
Man KKC, Ip P, Hsia Y, Chan EW, Chui CSL, Lam MPS, Wong WHS, Chow CB, Yung A, Wong ICK (2017) ADHD drug prescribing trend is increasing among children and adolescents in Hong Kong. J Atten Disord 21(14):1161–1168. https://doi.org/10.1177/1087054714536047
Morkem R, Patten S, Queenan J, Barber D (2017) Recent trends in the prescribing of ADHD medications in Canadian primary care. J Atten Disord:1087054717720719. https://doi.org/10.1177/1087054717720719
Nyarko KA, Grosse SD, Danielson ML, Holbrook JR, Visser SN, Shapira SK (2017) Treated prevalence of attention-deficit/hyperactivity disorder increased from 2009 to 2015 among school-aged children and adolescents in the United States. J Child Adolesc Psychopharmacol 27(8):731–734. https://doi.org/10.1089/cap.2016.0196
Piovani D, Clavenna A, Cartabia M, Bonati M (2016) Psychotropic medicine prescriptions in Italian youths: a multiregional study. Eur Child Adolesc Psychiatry 25(3):235–245. https://doi.org/10.1007/s00787-015-0726-0
Prosser B, Lambert MC, Reid R (2015) Psychostimulant prescription for ADHD in new South Wales: a longitudinal perspective. J Atten Disord 19(4):284–292. https://doi.org/10.1177/1087054714553053
Schubert I, Köster I, Lehmkuhl G (2010) The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German state of Hesse, 2000-2007. Dtsch Arztebl Int 107(36):615–621. https://doi.org/10.3238/arztebl.2010.0615
Song I, Shin JY (2016) Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011. Epidemiol Health 38:e2016045. https://doi.org/10.4178/epih.e2016045
Steinhausen HC, Bisgaard C (2014) Nationwide time trends in dispensed prescriptions of psychotropic medication for children and adolescents in Denmark. Acta Psychiatr Scand 129(3):221–231. https://doi.org/10.1111/acps.12155
Stuhec M, Locatelli I (2017) Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: a population-based study. Eur Psychiatry 42:129–133. https://doi.org/10.1016/j.eurpsy.2017.01.002
Zoëga H, Baldursson G, Hrafnkelsson B, Almarsdóttir AB, Valdimarsdóttir U, Halldórsson M (2009) Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 19(6):757–764. https://doi.org/10.1089/cap.2009.0003
Zoëga H, Furu K, Halldórsson M, Thomsen PH, Sourander A, Martikainen JE (2011) Use of ADHD drugs in the Nordic countries: a population-based comparison study. Acta Psychiatr Scand 123(5):360–367. https://doi.org/10.1111/j.1600-0447.2010.01607.x
Autti-Rämö I, Sourander A, Seppänen J, Martikainen JE (2011) Use of antidepressants among 0-26 year olds in Finland during 1997-2007. Eur J Psychiat 25(3):164–172. https://doi.org/10.4321/S0213-61632011000300006
Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Kalverdijk LJ, Petersen I, Schuiling-Veninga CC, Wijlaars L, Zito JM, Hoffmann F (2016) Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005-2012. Eur Neuropsychopharmacol 26(3):411–419. https://doi.org/10.1016/j.euroneuro.2016.02.001
Chien IC, Hsu YC, Tan HK, Lin CH, Cheng SW, Chou YJ, Chou P (2013) Trends, correlates, and disease patterns of antidepressant use among children and adolescents in Taiwan. J Child Neurol 28(6):706–712. https://doi.org/10.1177/0883073812450319
Chon MW, Lee J, Chung S, Kim Y, Kim HW (2017) Prescription pattern of antidepressants for children and adolescents in Korea based on nationwide data. J Korean Med Sci 32(10):1694–1701. https://doi.org/10.3346/jkms.2017.32.10.1694
Clavenna A, Andretta M, Pilati P, Dusi M, Gangemi M, Gattoni MB, Lombardo G, Zoccante L, Mezzalira L, Bonati M (2011) Antidepressant and antipsychotic use in an Italian pediatric population. BMC Pediatr 11(40). https://doi.org/10.1186/1471-2431-11-40
Dörks M, Langner I, Dittmann U, Timmer A, Garbe E (2013) Antidepressant drug use and off-label prescribing in children and adolescents in Germany: results from a large population-based cohort study. Eur Child Adolesc Psychiatry 22(8):511–518. https://doi.org/10.1007/s00787-013-0395-9
Foulon V, Svala A, Koskinen H, Chen TF, Saastamoinen LK, Bell JS (2010) Impact of regulatory safety warnings on the use of antidepressants among children and adolescents in Finland. J Child Adolesc Psychopharmacol 20(2):145–150. https://doi.org/10.1089/cap.2009.0040
Hartz I, Skurtveit S, Hjellvik V, Furu K, Nesvåg R, Handal M (2016) Antidepressant drug use among adolescents during 2004-2013: a population-based register linkage study. Acta Psychiatr Scand 134(5):420–429. https://doi.org/10.1111/acps.12633
Hoffmann F, Glaeske G, Bachmann CJ (2014) Trends in antidepressant prescriptions for children and adolescents in Germany from 2005 to 2012. Pharmacoepidemiol Drug Saf 23(12):1268–1272. https://doi.org/10.1002/pds.3649
John A, Marchant AL, Fone DL, McGregor JI, Dennis MS, Tan JO, Lloyd K (2016) Recent trends in primary-care antidepressant prescribing to children and young people: an e-cohort study. Psychol Med 46(16):3315–3327. https://doi.org/10.1017/S0033291716002099
Meng X, D’Arcy C, Tempier R (2014) Long-term trend in pediatric antidepressant use, 1983-2007: a population-based study. Can J Psychiatr 59(2):89–97. https://doi.org/10.1177/070674371405900204
O’Sullivan K, Boland F, Reulbach U, Motterlini N, Kelly D, Bennett K, Fahey T (2015) Antidepressant prescribing in Irish children: secular trends and international comparison in the context of a safety warning. BMC Pediatr 15:119. https://doi.org/10.1186/s12887-015-0436-2
Pottegård A, Zoëga H, Hallas J, Damkier P (2014) Use of SSRIs among Danish children: a nationwide study. Eur Child Adolesc Psychiatry 23(12):1211–1218. https://doi.org/10.1007/s00787-014-0523-1
Sarginson J, Webb RT, Stocks SJ, Esmail A, Garg S, Ashcroft DM (2017) Temporal trends in antidepressant prescribing to children in UK primary care, 2000-2015. J Affect Disord 210:312–318. https://doi.org/10.1016/j.jad.2016.12.047
Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, Riedel O (2017) Extent and risks of antidepressant off-label use in children and adolescents in Germany between 2004 and 2011. Pharmacoepidemiol Drug Saf 26(11):1395–1402. https://doi.org/10.1002/pds.4289
Steffenak AK, Wilde-Larsson B, Nordström G, Skurtveit S, Hartz I (2012) Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: a nationwide prescription database study. Clin Epidemiol 4:225–231. https://doi.org/10.2147/CLEP.S31624
Volkers AC, Heerdink ER, van Dijk L (2007) Antidepressant use and off-label prescribing in children and adolescents in Dutch general practice (2001-2005). Pharmacoepidemiol Drug Saf 16(9):1054–1062
Alessi-Severini S, Biscontri RG, Collins DM, Sareen J, Enns MW (2012) Ten years of antipsychotic prescribing to children: a Canadian population-based study. Can J Psychiatr 57(1):52–58. https://doi.org/10.1177/070674371205700109
Bachmann CJ, Lempp T, Glaeske G, Hoffmann F (2014) Antipsychotic prescription in children and adolescents: an analysis of data from a German statutory health insurance company from 2005 to 2012. Dtsch Arzteb Int 111(3):25–34. https://doi.org/10.3238/arztebl.2014.0025
Edelsohn GA, Karpov I, Parthasarathy M, Hutchison SL, Castelnovo K, Ghuman J, Schuster JM (2017) Trends in antipsychotic prescribing in Medicaid-eligible youth. J Am Acad Child Adolesc Psychiatry 56(1):59–66. https://doi.org/10.1016/j.jaac.2016.10.005
Hsu YC, Chien IC, Tan HK, Lin CH, Cheng SW, Chou YJ, Chou P (2013) Trends, correlates, and disease patterns of antipsychotic use among children and adolescents in Taiwan. Soc Psychiatry Psychiatr Epidemiol 48(12):1889–1896. https://doi.org/10.1007/s00127-013-0702-2
Kalverdijk LJ, Tobi H, van den Berg PB, Buiskool J, Wagenaar L, Minderaa RB, de Jong-van den Berg LT (2008) Use of antipsychotic drugs among Dutch youths between 1997 and 2005. Psychiatr Serv 59(5):554–560. https://doi.org/10.1176/ps.2008.59.5.554
Kalverdijk LJ, Bachmann CJ, Aagaard L, Burcu M, Glaeske G, Hoffmann F, Petersen I, Schuiling-Veninga CCM, Wijlaars LP, Zito JM (2017) A multi-national comparison of antipsychotic drug use in children and adolescents, 2005-2012. Child Adolesc Psychiatry Ment Health 11(55):55. https://doi.org/10.1186/s13034-017-0192-1
Lee H, Song DH, Han E, Kang HY (2018) Nationwide epidemiologic study of atypical antipsychotic use among pediatric population with mental illness in Korea. J Child Adolesc Psychopharmacol 28(3):205–215. https://doi.org/10.1089/cap.2017.0111
Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A (2018) Antipsychotics use: 2006-2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol 74(5):619–626. https://doi.org/10.1007/s00228-017-2406-0
Rani F, Murray ML, Byrne PJ, Wong IC (2008) Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 121(5):1002–1009. https://doi.org/10.1542/peds.2007-2008
Ronsley R, Scott D, Warburton WP, Hamdi RD, Louie DC, Davidson J, Panagiotopoulos C (2013) A population-based study of antipsychotic prescription trends in children and adolescents in British Columbia, from 1996 to 2011. Can J Psychiatr 58(6):361–369. https://doi.org/10.1177/070674371305800608
Schröder C, Dörks M, Kollhorst B, Blenk T, Dittmann RW, Garbe E, Riedel O (2017) Extent and risks of antipsychotic off-label use in children and adolescents in Germany between 2004 and 2011. J Child Adolesc Psychopharmacol 27(9):806–813. https://doi.org/10.1089/cap.2016.0202
Schubert I, Lehmkuhl G (2009) Increased antipsychotic prescribing to youths in Germany. Psychiatr Serv 60(2):269. https://doi.org/10.1176/appi.ps.60.2.269
Bénard-Laribière A, Noize P, Pambrun E, Bazin F, Verdoux H, Tournier M, Bégaud B, Pariente A (2016) Comorbidities and concurrent medications increasing the risk of adverse drug reactions: prevalence in French benzodiazepine users. Eur J Clin Pharmacol 72(7):869–876. https://doi.org/10.1007/s00228-016-2044-y
Cunningham CM, Hanley GE, Morgan S (2010) Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy 97(2–3):122–129. https://doi.org/10.1016/j.healthpol.2010.03.008
Hartz I, Furu K, Bratlid T, Handal M, Skurtveit S (2012) Hypnotic drug use among 0-17 year olds during 2004-2011: a nationwide prescription database study. Scand J Public Health 40(8):704–711. https://doi.org/10.1177/1403494812464446
John A, Marchant AL, McGregor JI, Tan JO, Hutchings HA, Kovess V, Choppin S, Macleod J, Dennis MS, Lloyd K (2015) Recent trends in the incidence of anxiety and prescription of anxiolytics and hypnotics in children and young people: an e-cohort study. J Affect Disord 183:134–141. https://doi.org/10.1016/j.jad.2015.05.002
O’Sullivan K, Reulbach U, Boland F, Motterlini N, Kelly D, Bennett K, Fahey T (2015) Benzodiazepine prescribing in children under 15 years of age receiving free medical care on the General Medical Services scheme in Ireland. BMJ Open 5(6):e007070. https://doi.org/10.1136/bmjopen-2014-007070
Sequi M, Campi R, Clavenna A, Bonati M (2013) Methods in pharmacoepidemiology: a review of statistical analyses and data reporting in pediatric drug utilization studies. Eur J Clin Pharmacol 69(3):599–604. https://doi.org/10.1007/s00228-012-1354-y
Reale L, Bartoli B, Cartabia M, Zanetti M, Costantino MA, Canevini MP, Termine C, Bonati M, Lombardy ADHD Group (2017) Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry 26(12):1443–1457. https://doi.org/10.1007/s00787-017-1005-z
Thomas R, Sanders S, Doust J, Beller E, Glasziou P (2015) Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics 135(4):e994–e1001. https://doi.org/10.1542/peds.2014-3482
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948. https://doi.org/10.1176/ajp.2007.164.6.942
Jorm AF, Patten SB, Brugha TS, Mojtabai R (2017) Has increased provision of treatment reduced the prevalence of common mental disorders? Review of the evidence from four countries. World Psychiatry 16(1):90–99. https://doi.org/10.1002/wps.20388
Arria AM, DuPont RL (2010) Nonmedical prescription stimulant use among college students: why we need to do something and what we need to do. J Addict Dis 29(4):417–426. https://doi.org/10.1080/10550887.2010.509273
Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63(3):332–339. https://doi.org/10.1001/archpsyc.63.3.332
Lee ES, Vidal C, Findling RL (2018) A focused review on the treatment of pediatric patients with atypical antipsychotics. J Child Adolesc Psychopharmacol 28(9):582–605. https://doi.org/10.1089/cap.2018.0037
Olfson M, King M, Schoenbaum M (2015) Treatment of young people with antipsychotic medications in the United States. JAMA Psychiatry 72(9):867–874. https://doi.org/10.1001/jamapsychiatry.2015.0500
Hilverdink P, Daamen W, Vink C (2015) Children and youth support and care in the Netherlands. Neth Youth Inst (www.nji.nl/english); Rapport (8). http://www.youthpolicy.nl/en/Download-NJi/Publicatie-NJi/Children-and-youth-support-and-care-in-The-Netherlands.pdf
Vitiello B (2008) An international perspective on pediatric psychopharmacology. Int Rev Psychiatry 20(2):121–126. https://doi.org/10.1080/09540260801887710
Kaplan GA, Shema SJ, Leite CM (2008) Socioeconomic determinants of psychological well-being: the role of income, income change, and income sources during the course of 29 years. Ann Epidemiol 18(7):531–537. https://doi.org/10.1016/j.annepidem.2008.03.006
World Health Organization and Calouste Gulbenkian Foundation (2014) Social determinants of mental health. World Health Organization, Geneva
Bonati M, Jacqz-Aigrain E, Choonara I (2017) Licensed medicines, off-label use or evidence-based. which is most important? Arch Dis Child 102:53–54. https://doi.org/10.1136/archdischild-2016-311527
Acknowledgements
The authors would like to acknowledge Judith Baggott for language editing.
Authors’ individual contributions
All the authors contributed equally to the design of the study. DP and AC reviewed the studies. DP wrote the first draft of the manuscript. AC contributed to writing the manuscript. MB supervised the study. All authors contributed to and have approved the final manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 50 kb)
Rights and permissions
About this article
Cite this article
Piovani, D., Clavenna, A. & Bonati, M. Prescription prevalence of psychotropic drugs in children and adolescents: an analysis of international data. Eur J Clin Pharmacol 75, 1333–1346 (2019). https://doi.org/10.1007/s00228-019-02711-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-019-02711-3